Mittempergher Lorenza, Delahaye Leonie Jmj, Witteveen Anke T, Snel Mireille Hj, Mee Sammy, Chan Bob Y, Dreezen Christa, Besseling Naomi, Luiten Ernest Jt
Research and Development, Agendia N.V., Science Park 406, 1098 XH Amsterdam, The Netherlands.
Product Support, Agendia Inc., 22 Morgan, Irvine, CA 92780, USA.
Transl Oncol. 2020 Apr;13(4):100756. doi: 10.1016/j.tranon.2020.100756. Epub 2020 Mar 21.
The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determination of these performance characteristics. BluePrint measures the expression of 80 genes that assess functional pathways which determine the intrinsic breast cancer molecular subtypes (i.e. Luminal-type, HER2-type, Basal-type). Knowing a tumor's dominant functional pathway can help allocate effective treatment to appropriate patients. Here we show that BluePrint is a highly precise and highly reproducible test with correlations above 98% based on the generated index and subtype concordance above 99%. Therefore, BluePrint can be used as a robust and reliable tool to identify breast cancer molecular subtypes.
多基因诊断特征的分析性能取决于许多参数，包括精密度、重复性、再现性和肿瘤内异质性。在此，我们通过测定这些性能特征来研究Blueprint 80基因乳腺癌分子亚型检测的分析性能。Blueprint检测80个基因的表达，这些基因评估决定内在乳腺癌分子亚型（即管腔型、HER2型、基底型）的功能通路。了解肿瘤的主要功能通路有助于为合适的患者分配有效的治疗方案。在此我们表明，Blueprint是一种高度精确且高度可重复的检测方法，基于生成的指数相关性高于98%，亚型一致性高于99%。因此，Blueprint可用作识别乳腺癌分子亚型的强大且可靠的工具。
